Pharma Business review is using cookies

ContinueLearn More
Close

News

August 20, 2018

FDA approves Bristol-Myers’ Opdivo to treat metastatic SCLC

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Opdivo as the first and only immuno-oncology treatment option for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.

FDA approves Bristol-Myers’ Opdivo to treat metastatic SCLC